(Reuters) - The document was released ahead of an FDA advisory panel meeting on Thursday to discuss the risks of using the erythropoiesis-stimulating agents in cancer patients.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment